Skip to main content
Fig. 3 | AMB Express

Fig. 3

From: Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease

Fig. 3

MG1363-pMG36e-GLP-1 reversed the pathological changes induced by MPTP. a, b MG1363-pMG36e-GLP-1 reduced the expression of TLR-4, p-IκBαand p-p65 on mouse brain induced by MPTP (IHC staining of substantia nigra). c, d MG1363-pMG36e-GLP-1 decreased the expression of p-AKT/AKT, p-GSK3β/GSK3β and β-catenin on mouse brain induced by MPTP (IHC staining of substantia nigra). e, f MG1363-pMG36e-GLP-1 alleviated the reduction of dopamine neurons on mouse brain induced by MPTP (IF staining of substantia nigra). C, control group (n = 8); AD, LPS group (n = 5); AD-G, LPS + 109 CFU MG1363-pMG36e-GLP-1 group (n = 5); PD, MPTP group (n = 8); PD-G, MPTP + 109 CFU MG1363-pMG36e-GLP-1 group (n = 8). Data are presented as mean ± SD. *p < 0.05

Back to article page